BioForm Medical, Inc.

Produces injectable implant products used in minimally invasive soft tissue augmentation procedures

Medical aesthetics company that produced injectable implant products used in minimally invasive soft tissue augmentation procedures

BioForm Medical was a medical aesthetics company focused on developing and commercializing products used by physicians to enhance a patient’s appearance. The company was a leader in the dermal filler market in the United States and Europe with its flagship product, RADIESSE®, for which it obtained FDA approval for the correction of moderate to severe folds and wrinkles in 2005. The company’s pipeline also included a number of additional aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. The company completed its initial public offering in 2007.

Transaction Summary

  • Essex Woodlands invested in BioForm in 2004, having identified the medical aesthetics space as an interesting, high growth area with no reimbursement risk.
  • In January 2010, Merz Pharma Group, a privately-held company based in Germany, announced the acquisition of BioForm Medical for $5.45 per share in cash, for a total equity value of approximately $253 million.
  • San Mateo, CA

  • Contact:
    Marty Sutter
  • www.bioform.com
  • Acquisition
  • Acquired by: Merz Pharma Group
  • Exit date: January 04, 2010
  • Logo

Related News

  • Merz to Acquire BioForm Medical
  • “Essex Woodlands was instrumental in BioForm's evolution and success. The entire EW team helped us assess technologies, revise and test our strategies, and test our assumptions and market vision. Our annual brainstorming session and update to the partnership proved to be one of our most valuable strategic review forums and helped us crystalize and refine BioForm's strategy.”

    Steve Basta